Literature DB >> 16861338

Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease.

Ari Zimran1, Deborah Elstein, Ernest Beutler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16861338     DOI： 10.1182/blood-2006-03-010801

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  No justification for very high-dose enzyme therapy for patients with type III Gaucher disease.

Authors:  Ari Zimran; Deborah Elstein
Journal:  J Inherit Metab Dis       Date:  2007-11       Impact factor: 4.982

Review 2.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

3.  Cellular Uptake of Glucocerebrosidase in Gaucher Patients Receiving Enzyme Replacement Treatment.

Authors:  Elena Gras-Colomer; María Amparo Martínez-Gómez; Ana Moya-Gil; Miguel Fernandez-Zarzoso; Matilde Merino-Sanjuan; Mónica Climente-Martí
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

4.  Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

Authors:  Raphael Schiffmann; Hasan Askari; Margaret Timmons; Chevalia Robinson; William Benko; Roscoe O Brady; Markus Ries
Journal:  J Am Soc Nephrol       Date:  2007-04-04       Impact factor: 10.121
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.